Gary Randall Fujimoto, MD
Occupational Medicine · Los Altos
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Fujimoto’s office at (650) 619-6011 to ask if they take your plan before you enroll.
California Medical Board record
Licence G43075 · Current
Licensed to practise in California · since 1980 · expires 2028-08-31 · Albert Einstein College of Medicine of Yeshiva University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$17,416 in 2025
| 2025 | 2 | 14 | $17,416 | $17,416 |
| 2024 | 2 | 11 | $10,019 | $10,019 |
| 2023 | 2 | 11 | $13,583 | $13,583 |
| 2022 | 1 | 4 | $2,720 | $2,720 |
| 2021 | 1 | 9 | $16,880 | $16,880 |
| 2020 | 3 | 5 | $2,119 | $3,225 |
| 2019 | 3 | 9 | $23,805 | $23,805 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | None | $11,135 | 8 payments
|
| Revance Therapeutics | Daxxify | $6,281 | 6 payments
|
See all 14 published payments
| Merck Sharp & Dohme | Consulting · 2025-12-15 | None | $340 |
| Merck Sharp & Dohme | Consulting · 2025-09-10 | None | $1,785 |
| Revance Therapeutics | Consulting · 2025-09-04 | Daxxify | $1,125 |
| Revance Therapeutics | Consulting · 2025-08-12 | Daxxify | $188 |
| Merck Sharp & Dohme | Consulting · 2025-07-16 | None | $1,615 |
| Revance Therapeutics | Consulting · 2025-07-07 | Daxxify | $281 |
| Merck Sharp & Dohme | Consulting · 2025-06-16 | None | $1,020 |
| Merck Sharp & Dohme | Consulting · 2025-06-04 | None | $680 |
| Revance Therapeutics | Consulting · 2025-06-04 | Daxxify | $1,875 |
| Revance Therapeutics | Consulting · 2025-05-21 | Daxxify | $2,625 |
| Merck Sharp & Dohme | Consulting · 2025-04-21 | None | $3,060 |
| Merck Sharp & Dohme | Consulting · 2025-03-17 | None | $1,360 |
| Revance Therapeutics | Consulting · 2025-02-24 | Daxxify | $188 |
| Merck Sharp & Dohme | Consulting · 2025-01-15 | None | $1,275 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $10,019
| Exelixis | None | $5,344 | 2 payments
|
| Merck Sharp & Dohme | None | $4,675 | 9 payments
|
2023: $13,583
| Merck Sharp & Dohme | None | $7,395 | 8 payments
|
| Exelixis | None | $6,188 | 3 payments
|
2022: $2,720
| Merck Sharp & Dohme | None | $2,720 | 4 payments
|
2021: $16,880
| Merck Sharp & Dohme | None | $16,880 | 9 payments
|
2020: $3,225
| Regeneron Pharmaceuticals | None | $1,838 | 2 payments
|
| Kite Pharma | Yescarta | $1,106 | 2 payments
|
| PTC Therapeutics | None | $281 | 1 payment
|
2019: $23,805
| Kite Pharma | Yescarta | $12,080 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | None | $6,738 | 2 payments
|
| Regeneron Pharmaceuticals | None | $4,988 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Prospective Study in Healthy Volunteers To Evaluate Patient-Centric Biosample Collection Using Low-Volume Smart Sampling and Smart Testing Devices · 2023 | Their institution | $299 |
Professional record
- NPI
- 1528122025
- Licence
- CA G43075California G43075: Current · expires 2028-08-31
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 2083X0100X (2083X0100X); Federal specialty code 2083P0901X (2083P0901X)
- Mailing address
- P.O. Box 3583, Los Altos, CA, 94024
- NPI first listed
- 2006-12-20
- NPI last updated
- 2015-05-06
This is when the NPI record was last certified, not a medical board exam.